Rhoda Smith, MD
General Surgery · Key West, FLNPI 1568564771
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Dilon Technologies, Inc. at 29.0% of the total. Reporting peaked in 2024 at $165 and has fallen 64.3% since, to $59 in 2025.
Across 18 payments — averaging $26.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dilon Technologies, Inc.$138
- Boston Scientific$130
- Medtronic$44
- TELA Bio, Inc.$43
- Pacira Pharmaceuticals Incorporated$40
- Mauna Kea Technologies, Inc.$27
- plus $56 from 3 others
What the payments were for
- Food & beverage$477100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dilon Technologies, Inc. | 2 | $138 |
| Boston Scientific | 6 | $130 |
| Medtronic | 2 | $44 |
| TELA Bio, Inc. | 2 | $43 |
| Pacira Pharmaceuticals Incorporated | 2 | $40 |
| Mauna Kea Technologies, Inc. | 1 | $27 |
| Innocoll Pharmaceuticals Limited | 1 | $20 |
| Mimedx Group, Inc. | 1 | $19 |
| Hologic Inc | 1 | $18 |
How this compares
$477 in reported general payments places this provider in the 80th percentile of 54 general surgery providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Erythromycin Ethylsuccinate | 12 | $11,354 |
| Pantoprazole Sodium | 309 | $4,982 |
| Famotidine | 146 | $2,027 |
| Omeprazole | 80 | $1,210 |
| Sucralfate | 21 | $602 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 33 | $329 |
Paid to pharmacies, not to this prescriber.
Other general surgery in Key West
- Paul WizmanBoca Raton$40K
- Mauricio HernandezMiami$20K
- Braulio SabatesCoral Gables$13K
- Michael BaptistaJacksonville$9K
- Juan SalazarCoral Gables$3K
- Roberto ComperatoreHialeah$3K
- Edgar RodasFort Lauderdale$2K
- Orlando PuenteMiami$1K
- Carlos BustamanteFort Myers$881
- Pete GarciaMiami$514
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.